CompanyGraph
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.66B, above the global median of $1.15B
- PositionReturn on equity is 28.4%, higher than 95% of its Biotechnology peers (median -24.5%)
- Interpretations5 currently firing — 5
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are production businesses; this one is a sense-making business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.66BUSDvs all stocks (USD)
Revenue (TTM)
907.29MUSDvs all stocks (USD)
52-Week Change
-41.71%vs all stocks
Market Capitalization
4.66BUSDvs all stocks (USD)
Enterprise Value
4.27BUSDvs all stocks (USD)
Forward P/E
46.36xvs Biotechnology peers
Price to Sales (TTM)
5.14xvs Biotechnology peers
Price to Book (MRQ)
7.85xvs Biotechnology peers
Enterprise to Revenue
4.71xvs Biotechnology peers
Enterprise to EBITDA
33.10xvs Biotechnology peers
Gross Margin
65.39%vs Biotechnology peers
Operating Margin
2.44%vs Biotechnology peers
Return on Assets (TTM)
9.31%vs Biotechnology peers
Return on Equity (TTM)
28.35%vs Biotechnology peers
Revenue (TTM)
907.29MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.96USDUpdated Jul 18, 2026Quarterly Revenue Growth
78.80%vs Biotechnology peers
Gross Profit (TTM)
625.32MUSDvs all stocks (USD)
EBITDA (TTM)
83.56MUSDvs all stocks (USD)
Net Income (TTM)
-411.42MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
78.78%vs Biotechnology peers
Operating Cash Flow (TTM)
147.37MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
102.06MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
812.03MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
272.87MUSDFY2025 · Dec 31, 2025Gross Profit
539.17MUSDFY2025 · Dec 31, 2025Operating Income
45.11MUSDvs all stocks (USD)
Pre-tax Income
-68.09MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-68.09MUSDFY2025 · Dec 31, 2025EBIT
-11.23MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
83.56MUSDFY2025 · Dec 31, 2025Research & Development
101.58MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
392.47MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
16.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
56.85MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.22USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.22USDFY2025 · Dec 31, 2025Basic Shares Outstanding
167.21MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
167.21MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-68.09MUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
85.43MUSDFY2025 · Dec 31, 2025Operating Cash Flow
4.65MUSDFY2025 · Dec 31, 2025Free Cash Flow
-11.61MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
800.04MUSDFY2025 · Dec 31, 2025Interest Paid
43.52MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-68.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
22.61MUSDFY2025 · Dec 31, 2025Stock-based Compensation
70.01MUSDFY2025 · Dec 31, 2025Other Non-cash Items
19.57MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-29.79MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
11.04MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.70MUSDFY2025 · Dec 31, 2025Capital Expenditures
-16.26MUSDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-16.26MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
27.86MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-106.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-113.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-30.26MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
647.08MUSDFY2025 · Dec 31, 2025Shares Outstanding
282.65MSharesUpdated Jul 18, 2026Float Shares
103.30MSharesUpdated Jul 18, 2026Shares Short
14.18MSharesUpdated Jul 18, 2026Short Ratio
4.75daysvs all stocks
Short % of Shares Outstanding
12.30%vs all stocks
% Held by Insiders
48.51%vs all stocks
% Held by Institutions
56.81%vs all stocks
Total Cash (MRQ)
823.46MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.91USDUpdated Jul 18, 2026Total Debt (MRQ)
430.96MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7261xvs Biotechnology peers
Current Ratio (MRQ)
7.05xvs Biotechnology peers
Book Value per Share (MRQ)
2.10USDUpdated Jul 18, 2026Total Assets
1.13BUSDvs all stocks (USD)
Total Current Assets
997.80MUSDFY2025 · Dec 31, 2025Total Liabilities
548.36MUSDFY2025 · Dec 31, 2025Total Non-current Assets
127.86MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
421.21MUSDFY2025 · Dec 31, 2025Total Current Liabilities
127.14MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
796.27MUSDFY2025 · Dec 31, 2025Other Short-term Investments
2.29MUSDFY2025 · Dec 31, 2025Accounts Receivable
112.14MUSDFY2025 · Dec 31, 2025Inventory
63.63MUSDFY2025 · Dec 31, 2025Accounts Payable
39.21MUSDFY2025 · Dec 31, 2025Short-term Debt
6.53MUSDFY2025 · Dec 31, 2025Deferred Revenue
24.49MUSDFY2025 · Dec 31, 2025Other Current Liabilities
327.00KUSDFY2025 · Dec 31, 2025Long-term Debt
421.16MUSDFY2025 · Dec 31, 2025Common Stock (Book)
283.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.55BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
577.31MUSDvs all stocks (USD)
Treasury Stock
16.90MUSDFY2025 · Dec 31, 202552-Week Low
14.19USDUpdated Jul 18, 202652-Week High
42.50USDUpdated Jul 18, 202652-Week Change
-41.71%vs all stocks
50-Day MA
17.00USDUpdated Jul 18, 2026200-Day MA
22.42USDUpdated Jul 18, 2026Avg 10-Day Volume
3.49MSharesUpdated Jul 18, 2026Avg 30-Day Volume
3.22MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.76USDUpdated Jul 18, 2026Other Income / Expense
-72.84MUSDFY2025 · Dec 31, 20255 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Debt Financing Activity
More cash moved through borrowing and repaying than through the business itself, and most of its debt is long-term.
Reads
How does this company use capital?
Diagnostic
Efficiency from Aging Assets
Revenue per asset reads high, partly because those assets are largely written down.
Reads
Diagnostic
Depreciation-Heavy Reported Profit
It reports a profit, and much of the gap to cash is depreciation rather than earnings.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is 28.4%, higher than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: 0.28Industry median: -0.25Industry P95: 0.23Peers compared: 197
Structural Tensions
Most companies in its industry are production businesses; this one is a sense-making businessSignificant
Industry peers: 502Share on the common pattern %: 98.00
Financial Health
Altman Z-Score 3.55: safe zoneNotable
Altman Z-Score: 3.55
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.66B, above the global median of $1.15BNotable
Market cap (USD): 4,661,404,660Global Median: 1,146,734,693.424
Revenue is $907.29M, above the global median of $520.53MNotable
Revenue (USD): 907,292,032Global Median: 520,528,949.311
Levered free cash flow is $102.06M, above the global median of $16.24MNotable
Levered free cash flow (USD): 102,059,248Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Medicilon Inc.
Tier 1SenseMakingApproval-Gated PipelineProduction
Fortrea Holdings Inc.
Tier 1SenseMakingApproval-Gated PipelineFlowInterface
Evotec SE
Tier 1SenseMakingApproval-Gated PipelineInterfaceProduction
Hvivo Plc
Tier 1SenseMakingApproval-Gated PipelineProductionRule
Ixico plc
Tier 1SenseMakingApproval-Gated PipelineProductionInterface
Fusion Antibodies Ltd.
Tier 1SenseMakingApproval-Gated PipelineProduction
Bechtle AG
Tier 3SenseMakingExpertise LeverageInterfaceFlow
Mphasis Ltd.
Tier 3SenseMakingExpertise LeverageFlowProduction
Science Applications International Corporation Common Stock
Tier 3SenseMakingExpertise LeverageProductionRule
Fti Consulting Inc.
Tier 3SenseMakingExpertise LeverageRuleInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Travere Therapeutics Inc.
3 interpretationsEfficiency from Aging AssetsIndustry-Benchmarked Return on Capital ElevatedDepreciation-Heavy Reported Profit
Enova International Inc.
2 interpretationsDebt Financing ActivityIndustry-Benchmarked Return on Capital Elevated
Puma Biotechnology Inc.
2 interpretationsEfficiency from Aging AssetsIndustry-Benchmarked Return on Capital Elevated